Qualigen Therapeutics, Inc. (QLGN)
NASDAQ: QLGN · Real-Time Price · USD
3.900
-0.060 (-1.52%)
Dec 20, 2024, 4:00 PM EST - Market closed
Qualigen Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Mar '20 Mar 31, 2020 | 2019 - 2015 |
| Revenue | - | - | - | 5.65 | 4.31 | 5.56 | Upgrade
|
| Revenue Growth (YoY) | - | - | - | 31.29% | -22.52% | -4.22% | Upgrade
|
| Cost of Revenue | 2.55 | 5.21 | 4.49 | 16.05 | 7.19 | 5.18 | Upgrade
|
| Gross Profit | -2.55 | -5.21 | -4.49 | -10.4 | -2.88 | 0.37 | Upgrade
|
| Selling, General & Admin | 4.15 | 6.1 | 10.27 | 12.27 | 8.42 | 1.88 | Upgrade
|
| Operating Expenses | 4.15 | 6.1 | 10.27 | 12.27 | 8.42 | 1.88 | Upgrade
|
| Operating Income | -6.7 | -11.3 | -14.76 | -22.66 | -11.3 | -1.5 | Upgrade
|
| Interest Expense | -1.04 | -1.52 | -0.03 | - | -0.14 | -0.28 | Upgrade
|
| Interest & Investment Income | 0.05 | - | - | 0.04 | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | 0.71 | 2.07 | 0.91 | 4.73 | -8.05 | 0 | Upgrade
|
| EBT Excluding Unusual Items | -6.99 | -10.76 | -13.89 | -17.89 | -19.49 | -1.78 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | -0.02 | - | - | - | - | Upgrade
|
| Asset Writedown | - | - | - | - | -1.38 | - | Upgrade
|
| Other Unusual Items | -0.79 | -1.7 | - | - | 0.45 | - | Upgrade
|
| Pretax Income | -7.77 | -12.48 | -13.89 | -17.89 | -20.42 | -1.78 | Upgrade
|
| Income Tax Expense | -0 | -0 | 0.01 | 0.01 | -0 | 0 | Upgrade
|
| Earnings From Continuing Operations | -7.77 | -12.48 | -13.89 | -17.9 | -20.42 | -1.79 | Upgrade
|
| Earnings From Discontinued Operations | -0.08 | -0.94 | -4.75 | - | - | - | Upgrade
|
| Net Income to Company | -7.85 | -13.42 | -18.64 | -17.9 | -20.42 | -1.79 | Upgrade
|
| Net Income | -7.85 | -13.42 | -18.64 | -17.9 | -20.42 | -1.79 | Upgrade
|
| Net Income to Common | -7.94 | -13.42 | -18.64 | -17.9 | -20.42 | -1.79 | Upgrade
|
| Shares Outstanding (Basic) | 0 | 0 | 0 | 0 | 0 | 0 | Upgrade
|
| Shares Outstanding (Diluted) | 0 | 0 | 0 | 0 | 0 | 0 | Upgrade
|
| Shares Change (YoY) | 98.44% | 32.09% | 30.91% | 102.67% | 158.37% | - | Upgrade
|
| EPS (Basic) | -41.51 | -132.25 | -242.69 | -305.05 | -705.37 | -159.54 | Upgrade
|
| EPS (Diluted) | -41.53 | -132.29 | -242.79 | -305.05 | -705.37 | -159.54 | Upgrade
|
| Free Cash Flow | -9.73 | -10.3 | -13.25 | -14.87 | -9.97 | 0.05 | Upgrade
|
| Free Cash Flow Per Share | -50.86 | -101.57 | -172.48 | -253.37 | -344.25 | 4.49 | Upgrade
|
| Gross Margin | - | - | - | -183.87% | -66.87% | 6.74% | Upgrade
|
| Operating Margin | - | - | - | -400.85% | -262.49% | -27.05% | Upgrade
|
| Profit Margin | - | - | - | -316.55% | -474.16% | -32.16% | Upgrade
|
| Free Cash Flow Margin | - | - | - | -262.93% | -231.41% | 0.91% | Upgrade
|
| EBITDA | -6.89 | -11.3 | -14.75 | -22.55 | -11.16 | -1.29 | Upgrade
|
| EBITDA Margin | - | - | - | - | -259.27% | -23.15% | Upgrade
|
| D&A For EBITDA | -0.18 | 0 | 0.01 | 0.11 | 0.14 | 0.22 | Upgrade
|
| EBIT | -6.7 | -11.3 | -14.76 | -22.66 | -11.3 | -1.5 | Upgrade
|
| EBIT Margin | - | - | - | - | -262.49% | -27.05% | Upgrade
|
| Revenue as Reported | - | - | - | 5.65 | 4.31 | 5.56 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.